Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Relmada Therapeutics Inc.

The latest announcement is out from Relmada Therapeutics ( ($RLMD) ). On July 28, 2026, Relmada Therapeutics appointed veteran biopharmaceutical ex...

Relmada Therapeutics Appoints New Chief Business Officer

In a report released today, Uy Ear from Mizuho Securities maintained a Buy rating on Relmada Therapeutics, with a price target of $19.00. According...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RLMD	$5.14	-1.81%	1.22M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RLMD	$5.14	-1.8%	1.22M
3
4
5
6

RLMD

RLMD

Get Relmada Therapeutics Inc. Data in Excel

Get Relmada Therapeutics Inc. Data in Excel